Skip to main content
Tianjin Ringpu Bio-Technology Co.,Ltd. logo

Tianjin Ringpu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 300119 ISIN · CNE100000TV1 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,285 across all filing types
Latest filing 2022-03-25 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 300119

About Tianjin Ringpu Bio-Technology Co.,Ltd.

https://www.ringpu.com

Tianjin Ringpu Bio-Technology Co.,Ltd. is a high-tech enterprise specializing in the research, development, production, and sale of animal health products. The company offers a comprehensive portfolio that includes veterinary biological products, chemical drugs, feed additives, and pet health solutions. Its product range covers vaccines for poultry and livestock, as well as various pharmaceutical formulations such as injections, powders, and oral solutions. Ringpu Bio-Technology emphasizes innovation through its dedicated R&D centers, focusing on disease prevention and treatment to support the global animal husbandry industry. The company provides integrated health management services and high-quality veterinary medicines to ensure food safety and animal welfare.

Recent filings

Filing Released Lang Actions
监事会关于2019年限制性股票激励计划回购注销部分限制性股票的核查意见
Transaction in Own Shares Classification · 95% confidence The document is a supervisory board opinion on the repurchase and cancellation of restricted stock under a 2019 restricted stock incentive plan. It references specific legal and regulatory frameworks related to stock incentive plans and details the number of shares repurchased and cancelled. The document is a formal opinion or verification related to a stock repurchase and cancellation event, not a full financial report or earnings release. It does not contain financial statements or earnings data but focuses on a specific corporate action regarding stock incentives. This fits best under the category of Transaction in Own Shares (POS), which covers company buybacks or share repurchase activities.
2022-03-25 Chinese
关于回购注销2019年限制性股票激励计划部分限制性股票的公告
Transaction in Own Shares Classification · 95% confidence The document is an official announcement from Tianjin Ruipu Biotechnology Co., Ltd. regarding the repurchase and cancellation of part of the 2019 restricted stock incentive plan shares. It details the reasons for the repurchase, the number of shares involved, pricing adjustments, the impact on share capital structure, and includes opinions from independent directors, the supervisory board, and legal counsel. The document is a formal announcement about a share repurchase related to an equity incentive plan, not a full financial report or earnings release. It does not contain financial statements or comprehensive financial data but focuses on the share repurchase transaction and related corporate governance approvals. Therefore, it fits best under the category of Transaction in Own Shares (POS), which covers company buybacks or cancellations of its own shares.
2022-03-25 Chinese
关于修改公司章程的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Tianjin Ruipu Biotechnology Co., Ltd. regarding amendments to the company's articles of association (company bylaws). It details specific changes to various articles, including capital changes due to share repurchase and cancellation, governance provisions, and procedural rules. The document is a formal public notice of these proposed amendments and states that the proposal will be submitted to the 2021 annual general meeting for approval. There is no financial statement, audit report, or detailed financial data included. The document is not a full annual report, interim report, or earnings release. It is not a proxy solicitation or voting results announcement but rather a regulatory announcement about changes to the company's governance documents and capital structure. Given the nature of the content and the fact it is an official announcement of changes to the company charter, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2022-03-25 Chinese
2021年度监事会工作报告
Management Reports Classification · 95% confidence The document is titled '2021 年监事会工作报告' which translates to '2021 Supervisory Board Work Report'. It details the supervisory board's activities during 2021, including meetings held, oversight of financial reports, compliance with laws and regulations, internal control evaluations, and supervision of company operations and related party transactions. It references the 2021 audited financial report and internal control self-evaluation report but does not itself contain full financial statements or detailed financial data. The document is a report from the supervisory board summarizing their oversight work for the year, which is a type of management or supervisory report rather than a full annual report or audit report. It is not a short announcement or certification but a substantive report on supervisory activities. Therefore, the best fitting category is Management Reports (MDA), which covers management's detailed explanation of financial results, business trends, and outlook, including supervisory board reports on company governance and oversight.
2022-03-25 Chinese
监事会关于2021年度内部控制自我评价报告的核查意见的公告
Audit Report / Information Classification · 95% confidence The document is a supervisory board's opinion on the company's 2021 internal control self-evaluation report. It references regulatory requirements and internal control frameworks but does not contain full financial statements or detailed financial data. The document is a formal audit or review opinion on internal controls, which aligns with an Audit Report / Information filing rather than a full Annual Report or Interim Report. The length is short and focused on internal control evaluation, fitting the AR category. FY 2021
2022-03-25 Chinese
独立董事2021年度述职报告（马闯）
Board/Management Information Classification · 95% confidence The document is titled '独立董事2021 年度述职报告' which translates to 'Independent Director 2021 Annual Work Report'. It is a detailed report by an independent director about their duties, attendance, opinions on major company matters, committee work, investor protection efforts, and training during the year 2021. The content focuses on governance, compliance with laws and regulations, and the director's role in overseeing company operations and protecting shareholder interests. There is no indication that this is an annual financial report (10-K), audit report, or earnings release. Instead, it is a management/governance-related report by a board member. This fits best under Board/Management Information (MANG) as it relates to the activities and responsibilities of a board member rather than a formal financial or regulatory filing. The document length is 3182 characters, which is relatively short but contains substantive content about board activities rather than just an announcement or certification. Therefore, the classification is MANG with high confidence.
2022-03-25 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.